Friday, April 3, 2009

Medical insurance call: a case of iridology

iridology of iris and eye The economic crisis apparently has an effect on my business: the patent consultancy has been falling off, and there is a notable increase in the demand to settle alternative medicine cases. It's all logical - people have less capital to secure their intellectual property, and less capital for conventional medical treatment. Hence, they turn to the soothsayers of the alternative medicine, which in the end are as brutal on the bank account as conventional medicine. The most recent case is that of iridology. The state insurance commission called me with the case of a patient that started to combine ear-nose-and-throat MD visits with visits to an iridologist. The lab tests for the last year showed plenty of vitamins, iron and a good liver profile. The patient complained of sinusitis, which really was a reaction to dry, furnace heating-dried air. Yet the iridologist decided that the patient's iris indicated a lack of selenium (!) as well as iron, which was responsible for the stuffy nose. The patient stopped going through with the MD's prescribed, over-the-counter treatments, and made other decisions that complicated medical insurance claims, and prompted me being called onto the scene. I immediately advise the patient to start using a vaporizer, which she had (ultrasonic), and she found a good deal on a hot-water vaporizer that can be attached to the furnace. She immediately reported relief in breathing through her nose. I made an appointment with the iridologist, and made a usual request for a free advice. In the process, I asked the iridologist very basic questions, which challenged the laughable principles of the scam:
  1. the founder of the iridology did not know enough about owl's eyes to start making deductions about human eye;
  2. the iris is an island in the middle of the eye, relying on the air for oxygen absorption, and on the nutrients seeping through the glassy matter of the eye;
  3. the only physical connection to the rest of the body is a nerve that controls dilation of the pupil.
  4. iridology has had no clue of the selenium inside the human body, for the last 150 years.
The iridologist has failed to show me the presence of iridology research materials analyzing the ENT problems. Nor did the iridologist produce any publications that are peer reviewed. She referred me to many of internet web sites that brag about case stories (not studies) where diagnoses were made using the owl's eye ideology of the scam's author, with no other lab or doctor-administered tests. I also challenged the iridologist to explain the difference between the iridology assessment of the selenium and iron deficiency, and the professional alb results consistently showing the contrary. That prompted the iridologist to say that iridologists and their patients are successful "because they have faith in it." QED. Case finished.

Wednesday, April 1, 2009

To buy or not to buy WordLogic

BUY: J. David Stewart, Analyst and Publisher, of the The Stewart Report (see this post) - A 25-year veteran of Wall Street, J. David Stewart is also a private professional investor, stock analyst and publisher of The Stewart Report (now in its 15th year of continuous publication). His acumen as an analyst specializing in small and micro-cap securities has earned him wide media attention, including feature stories in: Money, Fortune and Entrepreneur. He's also been quoted in The Washington Post, The Financial Post, The New York Times, The Financial Digest, Investor's Business Daily, The Dick Davis Digest and Barron's. The impact of his thinking is regularly reported in wire service dispatches by CBS Market Watch, Reuters, Bloomberg and Dow Jones News Service, and he is a frequent guest on national radio and television shows, including CNN. WordLogic Corporation's chart is one of the strongest I've seen in months. Admittedly, the recent market environment has resulted in a lot of very sickly looking stock charts, so I've been seeing some pretty bad stuff - but this picture would look outstanding even if I had nothing but bull-market winners to compare it to. After giving up roughly 90 percent of its value during the broad swoon that befell the entire market during 2008, WordLogic started bucking the general trend in early November and spent the next two months building a solid base from which to launch a New Year's rally - one that easily penetrated the short- (20-day), intermediate- (40-day) and long-term (180-day) moving averages, as well as a declining trend line that had represented minor upside resistance for more than six months. Since the beginning of the year, the stock has gained more than 200 percent, culminating on January 20 with a gap opening and subsequent move that tested the major resistance around 85 cents. Given the strong recent rally, I'd look for the stock to fail in this first attempt to break through that barrier, retrace to fill the gap on some short-term profit taking, then launch a rebound that will not only crack the major resistance but carry all the way to the $1.05-$1.10 level. If that takes some time, new resistance could build beyond that point - but if the stock gets there quickly, a further move carrying back to the 52-week high should follow close behind. The former Managing Editor of The Los Angeles Times Syndicate, Larry D. Spears has served as editor for America's foremost political and economic columnists, including Pulitzer Prize-winner Art Buchwald. As Editor of the Hume MoneyLetter, he polished the works of financial luminaries ranging from J. David Stewart to Wall Street Week host Louis Rukeyser and former U.S. Treasury Secretary William Simon. He also authored and edited "The SuperInvestor Files" for Hume Publishing and created the "100 Steps to Wealth" home-study course for Money Magazine. Currently, he is Editor-in-Chief for The Stewart Report and continues to specialize in the use of technical analysis and options trading, having authored four books on those subjects.

Wednesday, March 25, 2009

Intellectual Ventures buys up Transmeta's portfolio

Intellectual Ventures Symbol a typical Transmeta idea It is a rather interesting time to buy a microprocessor patent portfolio. Tech PC sales and related probably will drop a bit in 2009. From an article by Rick Merritt in EE Times, (01/28/2009 9:02 PM EST):
SAN JOSE, Calif. ‹ Intellectual Ventures, a patent development and licensing company, has acquired the patent portfolio of Transmeta Corp., a startup that made an unsuccessful bid to develop x86-compatible processors. The portfolio includes more than 140 issued U.S. patents and others pending and issued in the U.S. and elsewhere. The announcement comes as Novafora Inc., a venture-backed company founded in 2004, said it completed the $255.6 million acquisition of Transmeta originally announced in November. Novafora will use Transmeta's technology to boost its video processor designs; Intellectual Ventures will license the Transmeta technology on a non-exclusive basis. "The acquisition of the Transmeta semiconductor patents augments one of the most comprehensive patent portfolios in the semiconductor field which now includes more than 2,000 patents," said Paul Reidy, vice president of semiconductor licensing at Intellectual Ventures. "Some of the recently issued patents detail some of the most interesting breakthroughs in microprocessor architecture we've seen in the last decade or so," he added in a press statement. Transmeta had generated royalty revenues of about $300 million licensing its patents on areas such as low-power processors and code translation to chip makers including Intel Corp. Novafora did not indicate what role the patent transaction played in its purchase of Transmeta. "The addition of Transmeta's power management technology to our video processor will enable us to target Novafora's products to the broadest range of video-oriented devices," said Zaki Rakib, chief executive of Novafora. In November, Novafora announced it entered into a non-exclusive patent license agreement with Advanced Micro Devices. Under the terms of the agreement, AMD transferred to Transmeta 700,000 shares of Transmeta's Series B Preferred Stock held by AMD.